SecBot SecBot

MEOBF

MESOBLAST LTD
OTC· Biological Products, (No Diagnostic Substances)· Inc. C3· CIK 0001345099 Biotech & Drug Discovery
$1.32 +0.00 (+0.00%)
Oct 23 4:00 PM ET · prev $1.32
1 year
−21.4%
from $1.68 · Oct 27
30 days
−30.5%
from $1.90
52-week range
$1.14–1.97
−33% from high · low Sep 30
Avg volume 20D
600
Oct 1 spike 11.4K
Short interest
30.65M
−5.5%
Filing reports
8
analyzed by SecBot
SecBot read BULLISH 5 reports · latest
Balance 0 bearish · 4 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 5/5
Strongest BULLISH Mesoblast provided an ASX CEO Connect presentation on June 2, 2026, highlighting the successful U.S. launch…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersSTEADY

    Short interest −5.5% to 30.65M shares.

  • TrendDOWNTREND

    22% below its 50-day average.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jun 10, 2026 SEC
Mesoblast provided an ASX CEO Connect presentation on June 2, 2026, highlighting the successful U.S. launch of…
6-K — Impact 6/10
Apr 30, 2026 SEC
Mesoblast reported Q3 FY2026 Ryoncil net revenues of US$30.3M and a reduced net operating cash spend of US$4.1M, with…
6-K — Impact 6/10
Apr 16, 2026 SEC
Mesoblast Limited filed an 8-K with the SEC to report insider transactions, including on-market purchases of American…
6-K — Impact 3/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$54.9M
Next Q———$57.2M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
30,652,473
shares short
-5.5%
vs prior settlement
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Apr 16, 2026
Clinical Trial
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Crohn's Colitis
Phase 2 · TERMINATED
Apr 16, 2026
Clinical Trial
Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)
Phase 2 · TERMINATED
Mar 23, 2026
Clinical Trial
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
Phase 3 · COMPLETED

SecBot reports

8 filings · 6 bullish · 0 bearish · 2 neutral
All MEOBF filing & press-release reports (8)